Navigation Links
New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone)
Date:6/10/2008

adiversion.usdoj.gov/drugs_concern/oxycodone/oxycodone.htm" target="_new">http://www.deadiversion.usdoj.gov/drugs_concern/oxycodone/oxycodone.htm

About Chronic Pain

Approximately 50 million Americans suffer with chronic pain, a distinct type of pain, often with no cure. It can affect an individual throughout his or her life, lasting several weeks, months, or even years at a time. The onset of chronic pain may be nociceptive (caused by ongoing tissue injury), neuropathic (caused by damage to the brain, spinal cord, or peripheral nerves), or disease specific (such as osteoarthritis or cancer).

Corporate Relationships

In December 2002, DURECT licensed to Pain Therapeutics, Inc. the right to develop and commercialize on a worldwide basis Remoxy and other oral sustained release drug candidates using the ORADUR technology which incorporate four specified opioid compounds. Under the license agreement, DURECT is reimbursed for formulation and other work performed under its agreement with Pain Therapeutics, and will receive additional payments if certain development and regulatory milestones are achieved with respect to the licensed drug candidates. In addition, if commercialized, DURECT will receive royalties for Remoxy and certain other licensed drug candidates of between 6.0% to 11.5% of net sales of the drug candidate depending on sales volume as well as a mark-up on DURECT's supply of key excipients used in the manufacture of the licensed drug candidates. Pain Therapeutics sublicensed the commercialization rights to Remoxy and other licensed drug candidates to King Pharmaceuticals in November 2005.

About ORADUR

ORADUR is a proprietary technology designed to transform short-acting oral capsule dosage forms into sustained release oral products, with the added benefit of being less prone to abuse than other controlled release dosage forms on the market today.

About DURECT Corporation

DURECT is an emerging specialt
'/>"/>

SOURCE DURECT Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
3. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
4. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
5. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
6. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
7. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
8. Nitecs IND Application for Clinical Development With Lodotra Accepted by the FDA
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
11. Laser Energetics to Integrate BrightStar(TM) Alexandrite Lasers in Medical and Dental Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 The Conferee Networking committee is ... Conferee Networking. These two-hour sessions provide a unique networking ... resolve problems, discuss new techniques, or brainstorm new ideas ... a topic for consideration is August 31, 2014, and ... Conferee Networking committee will review the topics, and status ...
(Date:7/25/2014)... Pa. , July 25, 2014 /PRNewswire-iReach/ -- ... and consulting for global corporations operating in highly ... host its first annual Global User Group Conference, ... historic Philadelphia, Pennsylvania at ... - http://photos.prnewswire.com/prnh/20140724/130263 This ...
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... Nile Therapeutics,Inc. (OTC Bulletin Board: SPDU.OB), announced ... present at the Biotechnology Industry,Organization (BIO) Investor Forum ... Time at The Palace Hotel in San Francisco, ... and an update on its clinical,development programs, including ...
... Oct. 2 /PRNewswire/ - Respironics, Inc. (Nasdaq:,RESP) today ... outstanding shares,of Apollo Light Systems, Inc., a 20-year-old, ... therapy systems for melatonin suppression and,circadian rhythm sleep ... is located in American Fork, Utah and has ...
... 2 Monitorforhire.com, the,fastest source for hiring ... faster. The company has added a mobile ... immediately to work requests via,PDA or cell ... Freedman, president of monitorforhire.com says that adding ...
Cached Biology Technology:Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum 2Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum 3Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market 2Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market 3
(Date:7/27/2014)... and fungi can evade treatment by acquiring mutations in ... permanent mutations were once thought to be the only ... study has shown that microorganisms can use a temporary ... to gain the benefits of drug resistance without the ... a fungus called Mucor circinelloides, it is likely to ...
(Date:7/27/2014)... In an age of "big data," a single computer ... tasks must instead be distributed across a cluster of ... how Facebook and Google mine your web history to ... Netflix recommend your next favorite book or movie. But ... , New technologies for monitoring brain activity are generating ...
(Date:7/25/2014)... lived on the land now called California, and many ... of plants they used for food, fuel, tools, and ... desired habitat and natural resources. , Frank Lake, an ... will lead a field trip to the ... of America,s 99th Annual Meeting, in Sacramento, Cal. this ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New tools help neuroscientists analyze 'big data' 2New tools help neuroscientists analyze 'big data' 3New tools help neuroscientists analyze 'big data' 4New tools help neuroscientists analyze 'big data' 5Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... as we grow older, our bones become more brittle and ... of mass is a major reason for older bones fracturing ... on slowing down this loss. However, new research from scientists ... Laboratory (Berkeley Lab) shows that at microscopic dimensions, the age-related ...
... Winston-Salem, N.C. -- New research from Wake Forest ... electronics by developing, for the first time, an ... electrical properties, and inexpensive to produce. ... of physics at Wake Forest, her graduate students ...
... 2011 Neurotechnology , a provider ... the availability of SentiSight 3.0 , a Software ... version adds shape-based recognition and offers enhanced local-feature-based recognition ... also includes enhanced tracking of fast moving objects and ...
Cached Biology News:The brittleness of aging bones -- more than a loss of bone mass 2The brittleness of aging bones -- more than a loss of bone mass 3Flexible electronics hold promise for consumer applications 2SentiSight 3.0 Universal Object Recognition Technology Available Now From Neurotechnology 2SentiSight 3.0 Universal Object Recognition Technology Available Now From Neurotechnology 3SentiSight 3.0 Universal Object Recognition Technology Available Now From Neurotechnology 4
... AviTag E. coli Biotinylation Kit, Plasmid is designed ... E. coli expression kits. (Cat. No. 3 186 ... kit provides vectors for the easy introduction of ... expressed protein can be enzymatically mono-biotinylated by E. ...
... The ubiquitin-proteasome pathway is the major ... eukaryotic cells, where it catalyzes the ... and the rapid elimination of proteins ... 1998; Hochstrasser 1996). The critical protease ...
... technology enables sensitive, fast and specific detection ... Short hybridisation time ( ... chromosome spreads Multiplex capability Available ... Probes available with different labels. ...
... * Source rat ... T25 plated cells $550.00, * ... 120 population doublings, * This ... complete ,growth medium M55007-08 and ...
Biology Products: